Michael Böhm
Inserm
3 papers in the Anchorcite directory, published between 2019 and 2021, cited 18,208 times in total.
ORCID profileResearch topics
- Diabetes Treatment and Management · 3 papers
- Heart Failure Treatment and Management · 3 papers
- Cardiovascular Function and Risk Factors · 2 papers
- Chronic Kidney Disease and Diabetes · 1 paper
Frequent co-authors
- Piotr P. Ponikowski · 3 papers
- Vijay Chopra · 3 papers
- Béla Péter Merkely · 3 papers
- Subodh Verma · 3 papers
- Milton Packer · 2 papers
- Stefan D. Anker · 2 papers
- Javed Butler · 2 papers
- Gerasimos S Filippatos · 2 papers
Papers
- Dapagliflozin in Patients with Heart Failure and Reduced Ejection FractionNew England Journal of Medicine · 2019 · 7,529 citations
BACKGROUND: In patients with type 2 diabetes, inhibitors of sodium-glucose cotransporter 2 (SGLT2) reduce the risk of a first hospitalization for heart failure, possibly through glucose-independent mechanisms. More data are needed regarding the effects of SGLT2 inhibitors in patients with…
- Cardiovascular and Renal Outcomes with Empagliflozin in Heart FailureNew England Journal of Medicine · 2020 · 5,468 citations
BACKGROUNDSodium-glucose cotransporter 2 (SGLT2) inhibitors reduce the risk of hospitalization for heart failure in patients regardless of the presence or absence of diabetes.More evidence is needed regarding the effects of these drugs in patients across the broad spectrum of heart…
- Empagliflozin in Heart Failure with a Preserved Ejection FractionNew England Journal of Medicine · 2021 · 5,211 citations
BACKGROUND: Sodium-glucose cotransporter 2 inhibitors reduce the risk of hospitalization for heart failure in patients with heart failure and a reduced ejection fraction, but their effects in patients with heart failure and a preserved ejection fraction are uncertain. METHODS: In…
Metadata from OpenAlex (CC0).